Percutaneous Valve Innovations

This month, we feature the work, experience, and vision of 3 pioneers on the cutting edge of percutaneous therapies for heart valve disease:

            – Aortic: Didier Tchétché, MD

            – Mitral: Ted E. Feldman, MD                 

            – Tricuspid: Azeem Latib, MD

The Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF) Interventional Innovation Corner is headed by section editor Juan F. Granada, MD, Executive Director and Chief Innovation Officer; Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York.

Introduction

Juan F. Granada, MD

Catheter-based valve disease intervention is one of the most active areas of medical device innovation today. The transcatheter aortic valve replacement (TAVR) field continues to move forward very rapidly towards the development of lower profile devices targeting lower risk populations. In addition, over the last 2 years, several strategic companies have invested significant amount of resources on the mitral replacement field. Now, the tricuspid valve appears as the next logical target in this active field. However, many questions still remain including patient selection, implications of anatomical abnormalities in device selection and expected clinical benefit amongst high-risk patients.

This month, we took advantage of the lessons learned at the Transcatheter Valve Therapies (TVT) 2016 conference (June 16-18, Chicago), and feature the work, experience, and vision of 3 pioneers on the cutting edge of percutaneous therapies for heart valve disease.

Dr. Juan Granada can be contacted at jgranada@crf.org.

Click on each link below to reach the related article:

– Aortic: Didier Tchétché, MD

– Mitral: Ted E. Feldman, MD                 

– Tricuspid: Azeem Latib, MD